Purpose
|
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
|
Characteristics
|
Tradename: ZOLINZA Source of Compound: synthetic Target: HDAC inhibitor Receptor: HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 Status: USAN, INN
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
98?%
|
Formula
|
C14H20N2O3
|
Solubility
|
Soluble in water
|